Jennings Strouss is excited to be a part of this two day comprehensive conference on current developments in the Commercialization of Life Sciences Inventions. Frank Curci and Ron King, of TGen, are the Program Co-Chairs of this exciting conference and will be presenting on numerous topics. Also, Rick Lieberman will be moderating one of the panel discussions. Please see the attached event brochure for detailed agenda.
Life sciences companies and research institutions continue to look for innovative strategies to accelerate the commercialization of life sciences inventions by expediting the process from discovery, through development, and ultimately to the introduction of products and services into the marketplace.
This year's conference offers valuable guidance about the acceleration of the commercialization process by discussing new strategies that seek to streamline discovery and development challenges, reduce the development burden through multi-party collaborations and patent pools, accelerate the licensing of inventions from academic research institutions, and enhance the overall commercialization potential of products and services. The conference also addresses the proper structuring of start-up life sciences companies to attract adequate capital funding and take advantage of appropriate exit strategies, as well as new approaches to the valuation of intellectual property from the discovery stage to the marketplace.
Our faculty comes from leading life sciences research institutions, venture capital and investment banking firms, philanthropic foundations, law firms, intellectual property valuation companies, and other key industry professions. This faculty will offer insight on the most current developments concerning innovative ways of accelerating the "gap" from discovery and development to commercialization.
Join us for this timely opportunity to learn more about successful commercialization of life sciences inventions.
Program Co-Chairs: Frank X. Curci, Esq. and Ron G. King, Ph.D., MBA
Who Should Attend
In-house and private practice attorneys, life sciences researchers, technology transfer professionals, life sciences executives and representatives, consultants, agency and university officials, venture capitalists and investment bankers
Continuing Education Credits
This program qualifies for 12.25 AZ CLE credits. Upon request, we will apply for CLE credits in other states and other types of credits.
The conference will be held at the Sheraton Phoenix Downtown Hotel at 455 North 3rd Street in Phoenix, AZ 85004. You can reserve a sleeping room by going to www.spdcatering.com. This link will allow you to book your room and receive a special 20% discount because you are with Law Seminars International. Rooms are first come, first serve.
Frank X. Curci, Program Co-Chair, is a partner at Jennings, Strouss & Salmon, PLC and Chair of the Life Sciences, Biotechnology & Intellectual Property Groups. He represents life sciences and high tech companies in licensing, multi-party collaborations, technology and other IP matters. He is an elected member of the Arizona BioIndustry Association's Greater Phoenix Leadership Group.
Ron G. King, Ph.D., Program Co-Chair, is Vice President of New Ventures and Commercialization at TGen. Previously, he was the Associate Director for the National Human Genome Research Institute at the National Institutes of Health.
Richard Lieberman, Moderator, Chair of Jennings, Strouss & Salmon, PLC's Corporate, Securities and Finance Department, focuses on securities, corporate governance, M&A and finance. He is listed in The Best Lawyers in America.
Vicki L. Chandler, Ph.D., Director of the BIO5 Institute at the University of Arizona, is also the Carl E. and Patricia Weiler Endowed Chair for Excellence in Agriculture and Life Sciences and Regents' Professor in the Departments of Plant Sciences and Molecular and Cellular Biology.
Howard Clowes, partner at DLA Piper LLP, focuses on representing public companies, venture finance, M&A and corporate collaborations, especially in the life sciences industry. He is listed in The Best Lawyers in America.
Jeffrey Cossman, M.D. is Chief Scientific Officer of the Critical Path Institute (C-Path), and directs C-Path's Washington, DC-area office. He founded the Molecular Diagnostics Laboratory of the National Cancer Institute, NIH, and is listed in The Best Doctors in America.
Louis J. DeGennaro, Ph.D., Executive Vice President and Chief Scientific Officer at The Leukemia & Lymphoma Society, is responsible for the administration of research grant programs that support research leading to prevention, diagnosis and cure.
Mark G. Edwards is Principal at Deloitte Recap LLC, a member of Deloitte Touche Tohmatsu. Previously, he was Managing Director and Founder of Recombinant Capital, Inc.
Carlos Encinas, Ph.D., Director of the Technology Transfer Office at Cedars-Sinai Medical Center, provides support for the protection and commercialization of IP and promotes collaboration between investigators and other research institutes and universities.
Ronald J. Epperson, President and CEO of Intellectual Energy LLC, has experience in a variety of economic, business and financial analyses on behalf of clients in disputes involving intellectual property.
Jorge A. Goldstein, Ph.D., director at Sterne Kessler Goldstein and Fox PLLC, focuses on genomics, molecular and cell biology, recombinant DNA technology, immunology, transgenics, therapeutic methods, stem cells as well as organic synthesis, pharmaceuticals, and polymers. He is listed in The Best Lawyers in America and Chambers USA.
MaryAnn Guerra is President of TGen Accelerators, LLC and Chief Business Officer at TGen. She develops and establishes relationships that enhance scientific programs and accelerate the transfer of technology from the lab into new business opportunities.
Robert L. Jones, partner at Cooley Godward Kronish LLP, focuses on corporate partnering transactions. His clients include Five Prime Therapeutics, CoMentis, Gilead Sciences and Onyx Pharmaceuticals.
Michael J. Lasinski, Managing Director at Ocean Tomo, LLC, is in charge of the valuation practice area and focuses on strategy, valuation and tax structure analysis.
Thong Q. Le, Managing Director for WRF Capital, focuses on investment opportunities in biopharmaceuticals, medical devices, enterprise software and advanced materials. Previously, he was the Founder, President and CEO of MiniMeals, Inc.
Manoja R. Lecamwasam, Ph.D., Director of the Catholic Healthcare West Intellectual Innovation Network (CHWiin) office at Catholic Healthcare West, manages and commercializes all IP for the CHW Hospitals in Arizona, Nevada, and California.
Curt Malloy, President of the Infectious Disease Research Institute, focuses on the impact of both infectious diseases and IP law on the developing world. He is also an Adjunct Professsor at Seattle University.
Richard Mitchell, Ph.D. is Director of Business Development in Industry Relations and Technology Transfer at the Fred Hutchinson Cancer Research Center. Previously, he was Scientific Director, Marketing and Business Development with Nastech Pharmaceutical Company.
John W. Murphy, President and CEO of the Flinn Foundation, guides the programs which specialize in advancing the biosciences in Arizona. He is a member of the Governor's Council on Innovation and Technology.
William Newman, Ph.D. is Managing Director at Northwest Technology Ventures, LP, a seed fund focusing on ventures arising out of the research sector. He brings a business perspective to the academic and research environment, focusing on business development, technology transfer and venture investment.
R. Michael Rodgers is Chairman of Alare Capital Securities, LLC and is experienced in life sciences and technology-based companies. Previously, he was COO and CFO of the International Genomics Consortium.
Robert Tufel, Executive Director for The Ben & Catherine Ivy Foundation, is experienced in the health field, focusing on AIDS and brain tumors. Previously, he was Executive Director at the National Brain Tumor Foundation (NBTF).
Daniel C. Wood, CFA is General Partner at Mesa Verde Venture Partners, an early-stage bioscience venture capital fund focused on the Southwestern United States. Previously, he was Co-Founding General Partner of Inglewood Ventures of San Diego.